Molecular heterogeneity in hepatocellular carcinoma-Reference-Cited by-同舟云学术

Molecular heterogeneity in hepatocellular carcinoma

Published:2018-01-01 Issue:1 Volume:5 Page:HEP10
ISSN:2045-0923
Container-title:Hepatic Oncology
language:en
Short-container-title:Hepatic Oncology

Author:

Zhu Shijia¹,Hoshida Yujin¹

Affiliation:

1. Liver Tumor Translational Research Program, Harold C. Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

Publisher

Future Medicine Ltd

Subject

Oncology,Hepatology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/hep-2018-0005

Reference27 articles.

1. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

2. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

3. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

4. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

5. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correlation between 18F-FDG PET/CT metabolic parameters and microvascular invasion before liver transplantation in patients with hepatocellular carcinoma;Nuclear Medicine Communications;2024-09-13

2. Changes in Mutations of Cell-Free DNA and Liver Tumor Tissue in Patients with Advanced Hepatocellular Carcinoma before and after Introduction of Lenvatinib;Oncology;2024-07-24

3. DNA methylation regulator-based molecular subtyping and tumor microenvironment characterization in hepatocellular carcinoma;Frontiers in Immunology;2024-04-26

4. Cancer cell genetics shaping of the tumor microenvironment reveals myeloid cell-centric exploitable vulnerabilities in hepatocellular carcinoma;Nature Communications;2024-03-22

5. Correlation Between Low Cytoplasmic Expression of XBP1 and the Likelihood of Surviving Hepatocellular Carcinoma;In Vivo;2024